Novartis To Pay $9.7bn For The Medicines Company
Bid Follows Strong Data For Twice-Yearly Gene Silencing Cholesterol Lowerer
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
You may also be interested in...
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.
Two pharma companies have made an offer for Sorrento Therapeutics that could triple the pain management and immune-oncology specialist's value but the San Diego-based group is holding firm.